Poseida Therapeutics Inc. (NASDAQ:PSTX) saw an upside of 20.25% to $1.96 after adding $0.33 on Monday. The 5-day average trading volume is 1,472,469 shares of the company’s common stock. It has gained $2.6900 in the past week and touched a new high 2 times within the past 5 days. An average of 742,907 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,055,649.
PSTX’s 1-month performance is 0.51% or $0.0796 on its low of $1.6000 reached on 08/04/23. The company’s shares have touched a 52-week low of $1.54 and high of $8.82, with the stock’s rally to the 52-week high happening on 02/08/23. YTD, PSTX has lost -63.02% or -$3.2704 and has reached a new high 13 times. However, the current price is down -77.78% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
PSTX stock has a beta of 0.13. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.21 while the price-to-book (PB) in the most recent quarter is 1.07.
Poseida Therapeutics Inc.’s quick ratio for the period ended March 30 was 5.40, with the current ratio over the same period at 5.40. As well, the company’s long term debt to equity for the quarter ending March 30 was 0.37, while the total debt to equity was 0.37. The trailing 12-month EBITDA margin is -82.44% while for the period ending March 30, Poseida Therapeutics Inc.’s operating margin was -30.50%. The firm’s gross profit as reported stood at $190.44 million against revenue of $130.49 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Poseida Therapeutics Inc.’s cash and short-term investments amounted to $207.06 million against total debt of $87.89 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 103.78% to -$38.85 million, while revenue of -$33.93 million was 12.66% off the previous quarter. Analysts expected PSTX to announce -$0.45 per share in earnings in its latest quarter, but it posted -$0.45, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$40.16 million. PSTX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 156.06 million, with total debt at $87.89 million. Shareholders hold equity totaling $86.78 million.
Let’s look briefly at Poseida Therapeutics Inc. (PSTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 64.94% to suggest the stock is trending Neutral, with historical volatility in this time period at 117.67%.
The stock’s 5-day moving average is $1.7259, reflecting a +17.32% or $0.2996 change from its current price. PSTX is currently trading -3.81% above its 20-day SMA, -53.45% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -20.41% and SMA200 by-52.36%.
Stochastic %K and %D was 16.17% and 9.56% and the average true range (ATR) pointed at 0.2255. The RSI (14) points at 56.43%, while the 14-day stochastic is at 39.41% with the period’s ATR at 0.2108. The stock’s 9-day MACD Oscillator is pointing at 0.0449 and -0.0165 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Poseida Therapeutics Inc. (NASDAQ: PSTX), H.C. Wainwright launched coverage with a Buy rating. Analysts offering their rating for PSTX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate PSTX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is PSTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $17.00, with their median price target at $14.00. Looking at these predictions, the average price target given by analysts is for Poseida Therapeutics Inc. (PSTX) stock is $13.40.
